AI Article Synopsis

  • - Glaceum Inc. is testing HSG4112, a new anti-obesity drug, which has shown promise in improving energy use, normalizing weight, and being safe in initial trials.
  • - A 16-week trial will be conducted in South Korea with overweight and obese participants to assess the drug's safety and efficacy, employing a randomized, double-blind, placebo-controlled design.
  • - If successful, this trial could enhance the acceptance of HSG4112 among healthcare professionals and help manage chronic obesity-related conditions.

Article Abstract

Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company plans to conduct a phase 2a clinical trial to determine the safety and efficacy of HSG4112 in overweight and obese patients.

Methods: A 16-week randomised, double-blind, placebo-controlled, parallel-group trial will be conducted at five large hospitals in South Korea to assess the safety and efficacy of HSG4112 in overweight and obese patients. Participants who meet the inclusion/exclusion criteria will be assigned a subject number and randomly assigned to one of the four treatment groups (one group receiving a placebo) in a 1:1:1:1 ratio. The study's primary outcome will be to monitor the change in body weight (kg) from baseline to the end of treatment while monitoring safety and tolerability.

Discussion: This trial will evaluate the efficacy and safety of HSG4112 in overweight and obese adults. Upon proving the safety and effectiveness of the newly developed mechanism, it might significantly improve the perception of the product among medical personnel and obese patients. Furthermore, it may aid in managing chronic conditions that require long-term treatment. ClinicalTrials.gov, identifier [NCT05197556].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483829PMC
http://dx.doi.org/10.3389/fphar.2023.1177539DOI Listing

Publication Analysis

Top Keywords

hsg4112 overweight
16
overweight obese
16
obese patients
12
randomised double-blind
8
double-blind placebo-controlled
8
placebo-controlled parallel-group
8
phase clinical
8
clinical trial
8
safety efficacy
8
efficacy hsg4112
8

Similar Publications

Article Synopsis
  • - Glaceum Inc. is testing HSG4112, a new anti-obesity drug, which has shown promise in improving energy use, normalizing weight, and being safe in initial trials.
  • - A 16-week trial will be conducted in South Korea with overweight and obese participants to assess the drug's safety and efficacy, employing a randomized, double-blind, placebo-controlled design.
  • - If successful, this trial could enhance the acceptance of HSG4112 among healthcare professionals and help manage chronic obesity-related conditions.
View Article and Find Full Text PDF

Background: HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy.

Methods: In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure-activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and influence energy homeostasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!